Evidence map›Paper›PMID 35851303›Full record

ArticleScientific reports2022

COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study.

Amelia Sancilio, Joshua M Schrock, Alexis R Demonbreun, Richard T D'Aquila, Brian Mustanski, Lauren A Vaught, Nina L Reiser, Matt P Velez, Ryan R Hsieh, Daniel T Ryan and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Amelia SancilioInstitute for Policy Research, Northwestern University, Northwestern University, 1810 Hinman Ave, Evanston, IL, 60208, USA. amelia.sancilio@northwestern.edu.
Joshua M SchrockInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Evanston, USA.
Alexis R DemonbreunCenter for Genetic Medicine, Northwestern University, Evanston, USA.
Richard T D'AquilaDivision of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA.
Brian MustanskiInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Evanston, USA.
Lauren A VaughtCenter for Genetic Medicine, Northwestern University, Evanston, USA.
Nina L ReiserCenter for Genetic Medicine, Northwestern University, Evanston, USA.
Matt P VelezCenter for Genetic Medicine, Northwestern University, Evanston, USA.
Ryan R HsiehCenter for Genetic Medicine, Northwestern University, Evanston, USA.
Daniel T RyanInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Evanston, USA.
Rana SaberInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Evanston, USA.
Elizabeth M McNallyCenter for Genetic Medicine, Northwestern University, Evanston, USA.
Thomas W McDadeInstitute for Policy Research, Northwestern University, Northwestern University, 1810 Hinman Ave, Evanston, IL, 60208, USA.
Northwestern University · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
NCATS NIH HHS UL1 TR001422NIH HHS NIH 3UL1TR001422-06S4
6 · The paper itself

Abstract

Serological testing for SARS-CoV-2 IgG antibodies is used to assess their presence in blood samples from exposed individuals and provides a measure of the magnitude of immune response to infection. The measurement of neutralizing antibodies (NAbs) in particular provides information about the severity of prior infection and level of protective immunity against re-infection. Much of the work investigating the association between prior infection severity and NAb levels has been conducted among clinical populations, and less is known about this relationship in the general population. Accordingly, we utilize data from a large (n = 790) community-based cohort of unvaccinated, seropositive participants. We analyzed the association between NAb response, measured via surrogate virus neutralization assay, with patterns of symptoms and household exposure. Our results indicate no detectable NAb activity in 63.8% of the seropositive participants (n = 504). Those with detectable NAb levels demonstrated a positive relationship between NAb activity and both self-reported previous symptom severity and household exposure. These findings are significant in light of recent concerns about degree of protective immunity conferred by prior infection or vaccination, and we highlight the value of community-based research for investigating variation in immune response.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralFamily CharacteristicsHumansSARS-CoV-2Antibodies, NeutralizingAntibodies, Viral

Identifiers

PMID35851303
PMCPMC9293881
OpenAlexW4285728208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.